UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
chemistry (14) 14
human necessities (14) 14
hygiene (14) 14
medical or veterinary science (14) 14
metallurgy (14) 14
organic chemistry (14) 14
peptides (14) 14
preparations for medical, dental, or toilet purposes (14) 14
specific therapeutic activity of chemical compounds ormedicinal preparations (14) 14
beer (13) 13
biochemistry (13) 13
compositions or test papers therefor (13) 13
condition-responsive control in microbiological orenzymological processes (13) 13
enzymology (13) 13
measuring or testing processes involving enzymes, nucleicacids or microorganisms (13) 13
microbiology (13) 13
mutation or genetic engineering (13) 13
processes of preparing such compositions (13) 13
spirits (13) 13
vinegar (13) 13
wine (13) 13
life sciences & biomedicine (6) 6
science & technology (6) 6
lung cancer (5) 5
oncology (5) 5
chemotherapy (4) 4
humans (4) 4
mutation (4) 4
non-small cell lung carcinoma (4) 4
abridged index medicus (3) 3
analysis (3) 3
antineoplastic agents (3) 3
apoptosis (3) 3
b7-h1 antigen - metabolism (3) 3
biomarkers (3) 3
cancer therapies (3) 3
general & internal medicine (3) 3
ipilimumab (3) 3
lung cancer, non-small cell (3) 3
lung neoplasms (3) 3
medicine, general & internal (3) 3
nivolumab (3) 3
pd-l1 protein (3) 3
adult (2) 2
aged (2) 2
aged, 80 and over (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - adverse effects (2) 2
antineoplastic agents, immunological - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
cell survival (2) 2
clinical trials (2) 2
disease-free survival (2) 2
drug therapy (2) 2
female (2) 2
immunotherapy (2) 2
ipilimumab - administration & dosage (2) 2
ipilimumab - adverse effects (2) 2
ligands (2) 2
lung neoplasms - drug therapy (2) 2
male (2) 2
metastasis (2) 2
middle aged (2) 2
patient outcomes (2) 2
survival analysis (2) 2
tumors (2) 2
[sdv.bc]life sciences [q-bio]/cellular biology (1) 1
[sdv]life sciences [q-bio] (1) 1
airway management (1) 1
anaphylaxis (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antigen-antibody reactions (1) 1
antigens, cd274/metabolism; antineoplastic agents; carcinoma, non-small-cell lung/chemically induced; disease-free survival; humans; lung neoplasms/chemically induced (1) 1
antimitotic agents (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents, immunological (1) 1
antineoplastic agents, immunological - adverse effects (1) 1
antineoplastic combined chemotherapy protocols (1) 1
b7-h1 antigen (1) 1
b7-h1 antigen - genetics (1) 1
biomarkers, tumor (1) 1
body weight (1) 1
cancer (1) 1
cancer research (1) 1
carcinoma (1) 1
carcinoma, non-small-cell lung (1) 1
carcinoma, non-small-cell lung - chemically induced (1) 1
carcinoma, non-small-cell lung - genetics (1) 1
carcinoma, non-small-cell lung - metabolism (1) 1
carcinoma, non-small-cell lung - mortality (1) 1
care and treatment (1) 1
case-control studies (1) 1
cellular biology (1) 1
cetuximab (1) 1
clinical medicine (1) 1
colorectal cancer (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (25) 25
French (6) 6
Chinese (2) 2
German (2) 2
Korean (2) 2
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 05/2018, Volume 378, Issue 22, pp. 2093 - 2104
Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2017, Volume 376, Issue 25, pp. 2415 - 2426
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 21, pp. 2020 - 2031
Patients with advanced non–small-cell lung cancer with a PD-L1 expression level of 1% or more of tumor cells were randomly assigned to receive nivolumab plus... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Middle Aged | Carcinoma, Non-Small-Cell Lung - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Ipilimumab - adverse effects | Nivolumab - adverse effects | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Agents, Immunological - adverse effects | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Ipilimumab - administration & dosage | Nivolumab - administration & dosage | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Ipilimumab | Testing | Small cell lung carcinoma | Lung cancer | Non-small cell lung carcinoma | Oncology | Cancer therapies | Chemotherapy | Immunotherapy | PD-L1 protein | Biomarkers | Clinical medicine | Mutation | Drug dosages | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus | B7-H1 Antigen | Carcinoma, Non-Small-Cell Lung | Antineoplastic Combined Chemotherapy Protocols | Cellular Biology | Lung Neoplasms | Life Sciences | Antineoplastic Agents, Immunological | Nivolumab
Journal Article
Journal Article
Cancer medicine (Malden, MA), ISSN 2045-7634, 01/2015, Volume 4, Issue 1, pp. 36 - 42
Journal Article
Statistics in biopharmaceutical research, ISSN 1946-6315, 04/2020, Volume 12, Issue 2, pp. 187 - 198
The log-rank test is most powerful under proportional hazards (PH). In practice, non-PH patterns are often observed in clinical trials, such as in... 
Survival analysis | Nonproportional hazards | Fleming-Harrington test | Oncology trial | Log-rank test | Statistics & Probability | Physical Sciences | Mathematics | Life Sciences & Biomedicine | Science & Technology | Mathematical & Computational Biology
Journal Article
06/2020
개시내용은 높은 종양 돌연변이 부담 (TMB) 상태를 갖는 소세포 폐암 (SCLC)으로부터 유래된 종양을 앓고 있는 대상체에게 항-PD-1 항체를 포함하는 단독요법 또는 항-PD-1 항체 및 항-CTLA-4 항체를 포함하는 조합 요법을 투여하는 것을 포함하는, 높은 종양 돌연변이 부담... 
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS | WINE | MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS | HYGIENE | ENZYMOLOGY | ORGANIC CHEMISTRY | COMPOSITIONS OR TEST PAPERS THEREFOR | MEDICAL OR VETERINARY SCIENCE | MICROBIOLOGY | HUMAN NECESSITIES | BEER | MUTATION OR GENETIC ENGINEERING | SPIRITS | METALLURGY | PEPTIDES | PROCESSES OF PREPARING SUCH COMPOSITIONS | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | BIOCHEMISTRY | CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES | CHEMISTRY | VINEGAR
Patent
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.